Transcriptional regulation of cytochrome P4503A4 gene expression: effects of inherited mutations in the 5′-flanking region

References

• DAI, D., TANG, J., ROSE, R., HODGSON, E., BIENSTOCK, R. J., MOHRENWEISER, H. W. and GOLDSTEIN, J. A., 2001, Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics, 299, 825–831.
   PubMed Web of Science ®Google Scholar
• DALY, A. K., CHOLERTON, S., GREGORY, W. and IDLE, J. R., 1993, Metabolic polymorphisms. Pharmacology and Therapeutics, 57, 129–160.
   PubMed Web of Science ®Google Scholar
• DIGNAM, J., LEBOVITZ, R. and ROEDE R., 1983, Accurate transcription initiation by RNA polymerase-II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Research, 11, 1475–1489.
   PubMed Web of Science ®Google Scholar
• EL-SANKARY, W., BOMBAIL, V., GIBSON, G. G. and PLANT, N., 2002, Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metabolism and Disposition, 30, 1029–1034.
   Google Scholar
• EL-SANKARY, W., GIBSON, G. G., AYRTON, A. and PLANT, N., 2001, Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metabolism and Disposition, 29, 1499–1504.
   Google Scholar
• GIBSON, G., PLANT, N., SWALES, K., AYRTON, A. and E1-SANKARY, W., 2002, Receptor-dependent transcriptional activation of cytochrome P450 3A genes: induction mechanisms, species differences and inter-individual variation in man. Xenobiotica, 32, 165–206.
   Google Scholar
• GOODWIN, B., HODGSON, E. and LIDDLE, C., 1999, The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Molecular Pharmacology, 56, 1329–1339.
   PubMed Web of Science ®Google Scholar
• HAMZEIY, H., VAHDATI-MASHHADIAN, N., EDWARDS, H. J. and GOLDFARB, P. S., 2002, Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP. Mutation Research, 500, 103–110.
   Google Scholar
• HASHIMOTO, H., NAKAGAWA, T., YOKOI, T., SAWADA, M., ITOH, S. and KAMATAKI, T., 1995, Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster Cho cells have similar capacity to activate carcinogenic mycotoxins. Cancer Research, 55, 787–791.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO, H., TOIDE, K., KITAMURA, R., FUJITA, M., TAGAWA, S., ITOH, S. and KAMATAKI, T., 1993, Gene structure of CYP3A4, and adult specific form of cytochrome P450 in human livers, and its transcriptional control. European Journal of Biochemistry, 218, 585–595.
   PubMedGoogle Scholar
• HENRY, S. H., BOSCH, F. X., TROXELL, T. C. and BOLGER, P. M., 1999, Policy Forum: public health. Reducing liver cancer-global control of afiatoxin. Science, 286, 2453–2454.
   Google Scholar
• HSEIH, K -P., LIN, Y.-Y., CHENG, C.-L., LAI, M.-L., LIN, M.-S., SIEST, J.-P. and HUANG, J.-D., 2001, Novel mutations of CYP3A4 in chinease. Drug Metabolism and Disposition, 29, 268–273.
   Google Scholar
• HUSTERT, E., ZIBAT, A., PRESECAN-SIEDEL, E., EISELT, R., MUELLER, R., Fuss, C., BREHM, I., BRINKMANN, U., EICHELBAUM, M., WOJNOWSKI, L. and BURK, 0., 2001, Natural protein variants of pregnane X receptor with altered transactivation activity toward cyp3a4. Drug Metabolism and Disposition, 29, 1454–1459.
   Google Scholar
• KUEHL, P., ZHANG, J., LIN, Y., LANBA, J., ASSEM, M., SCHEUTZ, J., WATKINS, P., DALY, A., WRIGHTON, S., HALL, S., MAUREL, P., RELLING, M., BRIMER, C., YASUDA, K., VENKATARAMANAN, R., STROM, S., THUMMEL, K., BOGUSKI, M. and SCHUETZ, E., 2001, Sequence diversity in CYP3A promoters and characterisation of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 27, 383–391.
   PubMed Web of Science ®Google Scholar
• LAMBA, J. K., LIN, Y. S., SCHUETZ, E. G. and THUMMEL, K. E., 2002, Genetic contribution to variable human CYP3A-mediated metabolism. Advances in Drug Delivery Reviews, 54, 1271–1294.
   PubMed Web of Science ®Google Scholar
• LEHMANN, J. M., McKEE, D. D., WATSON, M. A., WILLSON, T. M., MOORE, J. T. and KLIEWER, S. A., 1998, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. Journal of Clinical Investigation, 102, 1016–1023.
   PubMed Web of Science ®Google Scholar
• NAKABAYASHI, H., TAKETA, K., MIYANO, K. Y., T. and SATO, J., 1982, Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Research, 42, 3858–3863.
   Google Scholar
• OZDEMIR, V., KALO W., TANG, B.-K., PATERSON, A., WALKER, S., ENDRENYI, L. and KASHUBA, A., 2000, Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 10, 373–388.
   Google Scholar
• PLANT, N., OGG, M., CROWDER, M. and GIBSON, G., 2000, Control and statistical analysis of in vitro reporter gene assays. Analytical Biochemistry, 278, 170–174.
   PubMed Web of Science ®Google Scholar
• QUATTROCHI, L. and GUZELIAN, P., 2001, CYP3A regulation: From pharmacology to nuclear receptors. Drug Metabolism and Disposition, 29, 615–622.
   PubMed Web of Science ®Google Scholar
• REBBICK, T., JAFFE, J., WALKER, A., VEIN, A. and MALKOWICZ, S., 1998, Modification of clinical presentation of prostate tumours by a novel genetic variant in CYP3A4. Journal of the National Cancer Institute, 90, 1225–1230.
   PubMedGoogle Scholar
• SAITO, T., TAKAHASHI, Y., HASHIMOTO, H. and KAMATAKI, T., 2001, Novel transcriptional regulation of the human CYP3A7 gene by Spl and Sp3 through nuclear factor kappa B-like element. Journal of Biological Chemistry, 276, 38010–38022.
   PubMed Web of Science ®Google Scholar
• SATA, F., SAPONE, A., ELIZONDO, G., STOCKER, P., MILLER, V., ZHENG, W., RAUNIO, H., CRESPI, C. and GONZALEZ, F., 2000, CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clinical Pharmacology and Therapeutics, 67, 48–56.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F., 1994, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals — studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• STOSCHECK, C., 1990, Quantitation of proteins. Methods in Enzymology, 182, 50–68.
   PubMed Web of Science ®Google Scholar
• WATKINS, P., 1994, The clinical significance of CYP3A enzymes. Pharmacogenetics, 4, 171–184.
   PubMedGoogle Scholar
• WESTLIND, A., LOFBERG, L., TINDBERG, N., ANDERSSON, T. B. and INGELMAN SUNDBERG, M., 1999, Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochemical and Biophysical Research Communications, 259, 201–205.
   PubMed Web of Science ®Google Scholar
• ZHANG, J., KUEHL, P., GREEN, E. D., TOUCHMAN, J. W., WATKINS, P. B., DALY, A., HALL, S. D., MAUREL, P., RELLING, M., BRIMER, C., YASUDA, K., WRIGHTON, S. A., HANCOCK, M., KIM, R. B., STROM, S., THUMMEL, K., RUSSELL, C. G., HUDSON, J. R., JR, SCHUETZ, E. G. and BoGusiG, M. S., 2001, The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics, 11, 555–572.
   Google Scholar